Clofarabine
Clofarabine is a second-generation nucleoside analog of adenosine. Clofarabine inhibits DNA polymerase and ribonucleotide reductase through binding in the A-site, preventing DNA synthesis. Clofarabine is clinically used to treat acute lymphoblastic leukemia (ALL) and is in clinical trials as a potential treatment for other leukemias. Clofarabine exhibits anticancer chemotherapeutic activity, acting as a cytotoxic agent. Clofarabine also binds A1, A2, and A3 adenosine receptors.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18852439
| Cas No. |
123318-82-1 |
|---|---|
| Purity |
≥98% |
| Formula |
C10H11ClFN5O3 |
| Formula Wt. |
303.68 |
| Chemical Name |
(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol |
| IUPAC Name |
(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol |
| Melting Point |
228-231°C |
| Solubility |
10mM H2O,100mM DMSO |
| Appearance |
White to off white powder |
Robak P, Robak T. Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev. 2013 Dec;39(8):851-61. PMID: 23566572.
Jensen K, Johnson LA, Jacobson PA, et al. Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 2012 May;385(5):519-25. PMID: 22249336.
Majda K, Lubecka K, Kaufman-Szymczyk A, et al. Clofarabine (2-chloro-2-fluoro-2-deoxyarabinosyladenine)–biochemical aspects of anticancer activity. Acta Pol Pharm. 2011 Jul-Aug;68(4):459-66. PMID: 21796927.
Aye Y, Stubbe J. Clofarabine 5-di and -triphosphates inhibit human ribonucleotide reductase by altering the quaternary structure of its large subunit. Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9815-20. PMID: 21628579.
Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5-triphosphate. Cancer Res. 1991 May 1;51(9):2386-94. PMID: 1707752.
